Haemonetics Corporation research snapshot
HAE AI stock analysis currently reads Haemonetics Corporation as a specialized medical technology company that just completed a four year transformation plan and is entering a cleaner fiscal 2027 with the CSL and whole blood portfolio transitions behind it. The analysis is not a certain price prediction. At the August 4, 2026 cutoff, the intraday price used here was $84.07, market capitalization was about $3.82 billion, and the stock had rallied roughly 14% from the mid July level to stand above its 20 day, 50 day, 100 day, and 200 day moving averages with a 14 day RSI near 76 in overbought territory. Fiscal 2026 revenue was about $1.33 billion with adjusted EPS of $4.96, and fiscal 2027 guidance targets 3% to 6% organic revenue growth and further margin expansion. The main question is whether plasma share gains, TEG momentum, and an interventional technology inflection can justify a forward P/E near 16x while GAAP earnings remain depressed and debt stays elevated. This is informational research and not investment advice.
Current price
$84.07
Market cap
$3.82 billion
AI score
65 / 100
Rating
Improving fundamentals, reasonable forward valuation, high debt
Trend status
Strong uptrend, price above all key moving averages, RSI overbought
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Haemonetics sells plasma collection, blood management, hemostasis, and vascular closure systems with recurring consumable and service revenue, an installed base, and a defensible position in hospital bleeding management. | Medium-high |
| Moat | The moat is built on switching costs from installed plasma and hospital equipment, proprietary disposables, FDA-cleared technology (TEG 6s, VASCADE, Persona PLUS), and long term plasma customer relationships. | Medium |
| Management | Management completed a four year transformation, beat Q4 FY26 expectations, guided fiscal 2027 to 3% to 6% organic growth, and earned a BofA upgrade with a $93 target. The track record on disciplined capital allocation is strengthening. | Medium-high |
| Financial trend | Fiscal 2026 revenue was about $1.33 billion with adjusted EPS of $4.96, up 9%, and adjusted operating margin of 25.4%. GAAP net income of $97 million was down about 42% year over year after one time charges. | Medium-high |
| Valuation | The stock trades at about 41x trailing earnings but only 16.4x forward earnings, reflecting an expected EPS inflection in fiscal 2027. EV/EBITDA is about 18.6x and FCF yield is roughly 6.6%. | Medium |
| Technical trend | HAE trades above its 20 day ($78.98), 50 day ($75.07), 100 day ($66.56), and 200 day ($67.82) moving averages after a sharp rally, but the 14 day RSI near 76 is overbought and ADX near 22 shows a moderate trend. | Medium-high |
| Risk level | Key risks are high total debt of about $1.2 billion (160% debt-to-equity), tariff exposure, plasma collection volume dependence, hospital capital spending cycles, FDA timing for PerQseal Elite, and competition in vascular closure. | Medium-high |
| AI confidence | Medium-high confidence for the business description, latest filings, guidance, market cap math, and major risk categories. Lower confidence for precise near-term revenue or earnings forecasts. | Medium-high data confidence |
| Investment certainty | Low-medium certainty. The forward earnings setup looks attractive if fiscal 2027 guidance is delivered, but debt leverage, tariffs, and plasma volume uncertainty limit conviction. | Low-medium |
HAE AI stock forecast
The HAE AI stock forecast uses scenario ranges around the $84.07 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires continued plasma share gains, Persona PLUS adoption, TEG momentum, an interventional technology rebound, and fiscal 2027 results above the top of guidance. The base case assumes HAE delivers the 3% to 6% organic growth range with steady margin improvement. The bearish case assumes plasma volume weakness, tariff escalation, hospital budget pressure, or continued vascular closure share losses.
$100 to $130
More likely if fiscal 2027 adjusted EPS exceeds the consensus near $5.20, Persona PLUS adoption accelerates, PerQseal Elite wins FDA approval, interventional technologies return to growth, and the stock re-rates toward 19 to 22x forward earnings near higher peer multiples.
$82 to $100
More likely if HAE delivers the 3% to 6% organic growth guidance, adjusted operating margin improves 50 to 100 basis points, adjusted EPS lands near $5.20, and the forward P/E holds near 16 to 18x.
$55 to $72
More likely if plasma collection volumes decline, tariffs rise further, hospital capital budgets tighten, VASCADE or SavvyWire lose share, or earnings miss guidance and the high debt load forces a de-rate toward 12 to 14x forward earnings.
HAE AI technical analysis
HAE AI technical analysis starts from the $84.07 intraday price used for this August 4 static page. Public technical sources showed the stock above its 20 day, 50 day, 100 day, and 200 day moving averages after a strong rally, with the 14 day RSI near 76 in overbought territory and the 52 week range around $47.32 to $88.28. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $84.07 | Intraday price from Yahoo Finance as of the August 4, 2026 data cutoff; prior close was about $85.42. |
| Near support | $79 to $80 | Support zone around the 20 day moving average ($78.98) reported by Barchart. |
| Secondary support | $74 to $76 | The 50 day moving average area ($75.07). A sustained close below this level would weaken the medium-term uptrend. |
| Long-term support | $66 to $68 | The 100 day and 200 day moving average zone ($66.56 and $67.82). A sustained break below the 200 day MA would challenge the long-term uptrend. |
| Near resistance | $86 to $88 | The recent 52 week high area. StockAnalysis showed a 52 week high of about $88.28, so a close above $88 would signal a new high. |
| 52-week high | $88.28 | The upper bound of the past 52 weeks reported by StockAnalysis on August 3, 2026. |
| 20-day moving average | $78.98 | Barchart showed HAE above the 20 day MA around the cutoff, supporting the short-term trend. |
| 200-day moving average | $67.82 | Public technical sources showed HAE above its 200 day MA, supporting the long-term trend. |
| Momentum | RSI 75.89, ADX 21.90 | RSI was overbought above 70. ADX near 22 indicated a moderate trend, and +DI at 36 was well above -DI at 15, confirming an uptrend bias. |
| Volume | About 594,000 shares (20 day average) | The recent volume snapshot was below the 50 day average of about 849,000, suggesting participation has cooled after the rally. |
| Volatility | ATR 14 near $2.70 (3.11%) | Position sizing should allow for normal daily movement of around 3.1% at the cutoff price. |
| Invalidation | Close below $79, then $75 | A close below the 20 day MA weakens the near-term setup. A break below the 50 day area would challenge the medium trend, and a break below the 200 day area would threaten the long trend. |
HAE AI trading strategy
The HAE AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels, with the next earnings report scheduled for August 6, 2026.
Look for HAE to hold above the 20 day area ($79) and the 50 day area ($75) on pullbacks, then confirm momentum with improving volume before treating the uptrend as established.
A daily close below the 20 day MA without quick recovery should reduce confidence in the near-term trend, and an RSI near 76 argues against chasing strength.
If HAE pulls back toward the 50 day or 200 day MA zone without fundamental deterioration, compare the entry with the August 6 earnings date, plasma volume data, and fiscal 2027 guidance delivery.
Do not average down solely because the forward P/E is low. Verify that the thesis drivers (plasma, TEG, vascular closure, margins) remain intact.
Track quarterly earnings, plasma collection volume and share gains, Persona PLUS adoption, TEG 6s placements, interventional technology revenue, PerQseal Elite FDA timing, and debt reduction progress in the new Apheresis and MedSurg reporting structure.
Lower the rating if free cash flow weakens while debt stays elevated, if tariffs compress gross margin, or if competitive pressure in vascular closure intensifies.
Investment research summary
Haemonetics provides medical devices and software for plasma collection, hospital hemostasis monitoring, surgical blood recovery, and vascular closure. Recurring consumable and service revenue from installed systems creates an annuity-like base, and the fiscal 2026 free cash flow of about $210 million reflects a capital-light model after the transformation.
The moat comes from regulatory-cleared installed equipment, proprietary single-use disposables, long-standing plasma customer contracts, the TEG 6s brand in viscoelastic testing, and the Persona PLUS yield enhancement that has been cleared by the FDA.
The thesis can fail if plasma collection volumes decline, tariffs compress margins, hospital capital budgets tighten, competitive products erode VASCADE or SavvyWire share, or the high debt load of about $1.2 billion restricts reinvestment while GAAP earnings stay weak.
Management completed a four year transformation plan, delivered a Q4 FY26 beat, and issued conservative fiscal 2027 guidance of 3% to 6% organic growth. The BofA upgrade to Buy with a $93 target and a new board member signal improving credibility, and capital allocation has shifted toward buybacks and the small Vivasure acquisition.
Haemonetics sits at the intersection of plasma-derived therapies, hospital patient blood management, and minimally invasive surgical closure. Plasma demand is structurally supported by growing immunoglobulin use, hospital focus on bleeding management is secular, and vascular closure is benefiting from rising electrophysiology procedure volumes despite PFA-related disruption in esophageal cooling.
At about 41x trailing earnings but only 16.4x forward earnings, the stock prices in a significant EPS recovery in fiscal 2027. The roughly 6.6% FCF yield provides some buffer, but the high debt, tariff sensitivity, and uneven GAAP earnings mean the margin of safety depends on delivery of guidance.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| HAE price | $84.07 intraday on August 4, 2026; prior close $85.42 | Yahoo Finance | August 4, 2026 |
| Market capitalization | $3.82 billion intraday, verified as $84.07 x 45.45M shares; StockAnalysis showed $3.93B | financial_rigor.py market cap verification and Yahoo Finance | August 4, 2026 |
| Revenue TTM | $1.33 billion | StockAnalysis and Yahoo Finance statistics | August 4, 2026 |
| Net income TTM | $97.31 million | StockAnalysis and Yahoo Finance statistics | August 4, 2026 |
| Diluted EPS TTM | $2.05 | StockAnalysis and Yahoo Finance statistics | August 4, 2026 |
| Forward P/E | 16.37x (Yahoo), 16.58x (StockAnalysis) | Yahoo Finance statistics and StockAnalysis | August 4, 2026 |
| Levered free cash flow TTM | $298.09 million | Yahoo Finance statistics and financial_rigor.py | August 4, 2026 |
| Cash and cash equivalents | $246.26 million | Yahoo Finance balance sheet | August 4, 2026 |
| Total debt and net leverage | Total debt about $1.2 billion, net leverage 2.73x EBITDA per the Q4 FY26 release | Haemonetics Q4 FY26 earnings release and Yahoo Finance | August 4, 2026 |
| Total debt / equity | 160.08% | Yahoo Finance statistics | August 4, 2026 |
| Valuation math | 41.67x trailing PE, 3.03x price-to-sales, 4.87x price-to-book, 18.11x EV/EBITDA, 6.57% FCF yield from financial_rigor.py | financial_rigor.py valuation verification | August 4, 2026 |
| Moving averages and momentum | 20-day MA $78.98, 50-day MA $75.07, 200-day MA $67.82, 14-day RSI 75.89, ADX 21.90 | Barchart technical analysis | August 4, 2026 |
| Fiscal 2026 results and guidance | FY26 revenue $1.33 billion, adjusted EPS $4.96, adjusted operating margin 25.4%; FY27 guidance 3% to 6% organic growth | Haemonetics Q4 FY26 earnings release and call transcript | August 4, 2026 |
| Analyst consensus | Buy rating with an average target of about $87.90 and a range of $62 to $104; BofA raised its target to $93 on July 29, 2026 | StockAnalysis analyst summary and TheFly news | August 4, 2026 |
This HAE AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 4, 2026 and can be wrong.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
